Actively Recruiting
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
Led by The First Affiliated Hospital of Xiamen University · Updated on 2024-07-31
50
Participants Needed
1
Research Sites
417 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This was a retrospective study. Children who were diagnosed with refractory nephrotic syndrome and treated with rituximab (RTX) and followed up for ≥1 year in the Department of Pediatrics, the First Affiliated Hospital of Xiamen University from March 2020 to March 2026 were enrolled. Personal information, past medical history, clinical examination data and follow-up data before and after the use of RTX were extracted from the medical record system. (1) The median relapse-free survival, the number of relapses and the adverse reactions of RTX were compared before and after RTX treatment, and the clinical efficacy and safety of RTX were evaluated. (2) By comparing the annual relapse frequency, reduction and withdrawal of steroids and immunosuppressive agents, B cell reconstitution and adverse drug reactions between prophylactic RTX and post-relapse RTX maintenance regimens; (3) Multivariate analysis of risk factors for recurrence of nephropathy after RTX treatment. (4) growth indicators monitoring patient evaluation and RTX medical economic benefit analysis.
CONDITIONS
Official Title
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children clinically diagnosed with FRNS/SDNS/SRNS with complete clinical data
- Age less than 18 years old
- First time using rituximab treatment for nephrotic syndrome
- Follow-up period of 1 year or more
You will not qualify if you...
- Congenital or infantile nephrotic syndrome or secondary nephrotic syndrome such as lupus nephritis, IgA nephropathy, purpura nephritis, hepatitis B nephritis
- Active hepatitis, severe infection, severe immune deficiency, or malignant diseases
- Estimated glomerular filtration rate (GFR) less than 60 mL/min/1.73m2
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
First affiliated hospital of xiamen university
Xiamen, Fujian, China, 361003
Actively Recruiting
Research Team
B
Bai HaiTao, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here